导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.92% | 373/4773 |
| 近一周 | -2.02% | 1085/5462 |
| 近一月 | -7.57% | 3876/5421 |
| 近一季 | -11.98% | 3791/5209 |
| 近半年 | 14.04% | 326/4920 |
| 近一年 | 19.85% | 420/4366 |
| 近两年 | 131.28% | 325/2954 |
| 近三年 | 87.74% | 196/2253 |
| 成立以来 | 41.35% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.98% 3991/4961 |
71.35% 256/5312 |
- - |
- - |
| 2025 | 37.73% 889/4813 |
2.72% 1282/3635 |
-0.23% 2855/4076 |
43.04% 666/4524 |
-6.05% 3664/4813 |
| 2024 | 18.19% 621/3463 |
-7.01% 2107/2808 |
-0.63% 803/3014 |
15.13% 1805/3129 |
11.11% 241/3463 |
| 2023 | 2.48% 315/2656 |
24.21% 105/2280 |
-6.55% 1666/2385 |
-10.18% 1970/2515 |
-1.70% 360/2655 |
| 2022 | -31.55% 1659/2207 |
-22.28% 1692/1919 |
-0.69% 1647/2016 |
-15.93% 1372/2113 |
5.49% 463/2208 |
| 2021 | 8.11% 485/1822 |
-9.50% 1108/1255 |
17.58% 184/1330 |
-6.88% 1004/1466 |
9.10% 128/1822 |
| 2020 | 19.54% 733/1250 |
-0.86% 195/1028 |
22.43% 208/1067 |
-0.13% 1051/1164 |
-1.38% 1104/1184 |
| 2019 | 52.20% 91/1092 |
40.98% 43/739 |
-10.19% 727/788 |
10.79% 46/850 |
8.51% 309/918 |
| 2018 | -31.50% 496/834 |
- - |
-15.81% 535/631 |
-10.46% 542/660 |
-12.38% 440/682 |
| 2017 | 0.07% 481/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发信息技术联接C VS. 长安沪深300非周期A(740101) |